Laboratory diagnosis of pneumonia in the molecular age

European Respiratory Journal

Volumn 48, Issue 6, 2016, Pages 1764-1778

  Torres, Antoni ^a   Lee, Nelson ^b   Cilloniz, Catia ^a   Vila, Jordi ^c   Van Der Eerden, Menno ^d  

^a HOSPITAL CLÍNIC   (Spain)

^b and Hong Kong Branch of CAS Center for Excellence in Animal Evolution and Genetics   (Hong Kong)

^c CENTRE FOR RESEARCH IN ENVIRONMENTAL EPIDEMIOLOGY CREAL   (Spain)

^d ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIUM DETECTION; CLINICAL PRACTICE; DIAGNOSTIC PROCEDURE; DIAGNOSTIC TEST; HUMAN; INFLUENZA VIRUS; LABORATORY DIAGNOSIS; LEGIONELLA PNEUMOPHILA; LOWER RESPIRATORY TRACT INFECTION; MICROBIOLOGICAL EXAMINATION; MICROBIOME; MOLECULAR DIAGNOSIS; MYCOPLASMA PNEUMONIAE; NONHUMAN; PNEUMONIA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REVIEW; SPUTUM CULTURE; STREPTOCOCCUS PNEUMONIAE; VIRUS PNEUMONIA; PROCEDURES;

ANTIINFECTIVE AGENT;

ANTI-BACTERIAL AGENTS; HUMANS; MICROBIOLOGICAL TECHNIQUES; MOLECULAR DIAGNOSTIC TECHNIQUES; PNEUMONIA;

EID: 85006173354     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/13993003.01144-2016     Document Type: Review

References (116)

1. Centers for Disease Control and Prevention (CDC). Control of Infectious Diseases. MMWR Morb Mortal Wkly Rep 1999; 48: 621-629.
2. Naghavi M, Wang H, Lozano, R, et al. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: A systematic analysis for the Global Burden of Disease Study 2013. Lancet 2015; 385: 117-171.
3. Musher DM, Thorner AR. Community-Acquired pneumonia. N Engl J Med 2014; 371: 1619-1628.
4. Bonten MJ, Huijts SM, Bolkenbaas M, et al. Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. N Engl J Med 2015; 372: 1114-1125.
5. Welte T, Torres A, Nathwani D. Clinical and economic burden of community-Acquired pneumonia among adults in Europe. Thorax 2012; 67: 71-79.
6. File TM Jr, Marrie TJ. Burden of community-Acquired pneumonia in North American adults. Postgrad Med 2010; 122: 130-141.
7. Song JH, Thamlikitkul V, Hsueh PR. Clinical and economic burden of community-Acquired pneumonia amongst adults in the Asia-Pacific region. Int J Antimicrob Agents 2011; 38: 108-117.
8. Ewig S, Torres A. Community-Acquired pneumonia as an emergency: Time for an aggressive intervention to lower mortality. Eur Respir J 2011; 38: 253-260.
9. Garau J, Baquero F, Perez-Trallero E, et al. Factors impacting on length of stay and mortality of community-Acquired pneumonia. Clin Microbiol Infect 2008; 14: 322-329.
10. Barlow G, Nathwani D, Williams F, et al. Reducing door-To-Antibiotic time in community-Acquired pneumonia: controlled before-And-After evaluation and cost-effectiveness analysis. Thorax 2007; 62: 67-74.
11. Yu KT, Wyer PC. Evidence-based emergency medicine/critically appraised topic. Evidence behind the 4-hour rule for initiation of antibiotic therapy in community-Acquired pneumonia. Ann Emerg Med 2008; 51: 651-662.
12. Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-Acquired pneumonia in adults. Clin Infect Dis 2007; 44: Suppl. 2, S27-S72.
13. Aliberti S, Di Pasquale M, Zanaboni AM, et al. Stratifying risk factors for multidrug-resistant pathogens in hospitalized patients coming from the community with pneumonia. Clin Infect Dis. 2012; 54: 470-478.
14. Shorr AF, Zilberberg MD, Micek ST, et al. Prediction of infection due to antibiotic-resistant bacteria by select risk factors for health care-Associated pneumonia. Arch Intern Med 2008; 168: 2205-2210.
15. Prina E, Ranzani OT, Polverino E, et al. Risk factors associated with potentially antibiotic-resistant pathogens in community-Acquired pneumonia. Ann Am Thorac Soc 2015; 12: 153-160.
16. Houck PM, Bratzler DW, Nsa W, et al. Timing of antibiotic administration and outcomes for Medicare patients hospitalized with community-Acquired pneumonia. Arch Intern Med 2004; 164: 637-644.
17. Waterer GW, Kessler LA, Wunderink RG. Delayed administration of antibiotics and atypical presentation in community-Acquired pneumonia. Chest 2006; 130: 11-15.
18. Cilloniz C, Gabarrus A, Ferrer M, et al. Community-Acquired pneumonia due to multidrug and non-multidrug resistant Pseudomonas aeruginosa. Chest 2016; 150: 415-425.
19. Douglas IS. New diagnostic methods for pneumonia in the ICU. Curr Opin Infect Dis 2016; 29: 197-204.
20. Shindo Y, Ito R, Kobayashi D, et al. Risk factors for drug-resistant pathogens in community-Acquired and healthcare-Associated pneumonia. Am J Respir Crit Care Med 2013; 188: 985-995.
21. Chalmers JD, Taylor JK, Singanayagam A, et al. Epidemiology, antibiotic therapy, and clinical outcomes in health care-Associated pneumonia: A UK cohort study. Clin Infect Dis 2011; 53: 107-113.
22. Van Boeckel TP, Gandra S, Ashok A, et al. Global antibiotic consumption 2000 to 2010: An analysis of national pharmaceutical sales data. Lancet Infect Dis 2014; 14: 742-750.
23. Aliberti S, Cilloniz C, Chalmers JD, et al. Multidrug-resistant pathogens in hospitalised patients coming from the community with pneumonia: A European perspective. Thorax 2013; 68: 997-999.
24. Giamarellou H, Poulakou G. Multidrug-resistant Gram-negative infections: What are the treatment options? Drugs 2009; 69: 1879-1901.
25. The Center for Disease Dynamics, Economics and Policy. The State of the World's Antibiotics 2015. Washington, The Center for Disease Dynamics, Economics and Policy (CDDEP), 2015. Available from: https://cddep.org/sites/default/files/swa-2015-final.pdf.
26. Chahwakilian P, Huttner B, Schlemmer B, et al. Impact of the French campaign to reduce inappropriate ambulatory antibiotic use on the prescription and consultation rates for respiratory tract infections. J Antimicrob Chemother 2011; 66: 2872-2879.
27. McDonagh M, Peterson K, Winthrop K, et al. Improving antibiotic prescribing for uncomplicated acute respiratory tract infections [Internet]. AHRQ Comparative Effectiveness Reviews 2016; 163: 5(16)-EHC033-EF.
28. National Action Plan for Combating Antibiotic-Resistant Bacteria. Washington, The White House, 2015. Available from: Www.whitehouse.gov/sites/default/files/docs/national-Action-plan-for-combating-Antibotic-resistant-bacteria.pdf.
29. U.S. Food & Drug Administration (FDA). News Release: New FDA task force will support innovation in antibacterial drug development. Silver Spring, MD, U.S. Food & Drug Administration (FDA), 24 September 2012. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm320643.htm; Page last updated: September 24, 2012.
30. van der Eerden MM, Vlaspolder F, de Graaff CS, et al. Value of intensive diagnostic microbiological investigation in low-And high-risk patients with community-Acquired pneumonia. Eur J Clin Microbiol Infect Dis 2005; 24: 241-249.
31. Roson B, Carratala J, Dorca J, et al. Etiology, reasons for hospitalization, risk classes, and outcomes of community-Acquired pneumonia in patients hospitalized on the basis of conventional admission criteria. Clin Infect Dis 2001; 33: 158-165.
32. Lim WS, Macfarlane JT, Boswell TC, et al. Study of community acquired pneumonia aetiology (SCAPA) in adults admitted to hospital: implications for management guidelines. Thorax 2001; 56: 296-301.
33. Waterer GW, Wunderink RG. The influence of the severity of community-Acquired pneumonia on the usefulness of blood cultures. Respir Med 2001; 95: 78-82.
34. Polverino E, Torres A. Community-Acquired penumonia. Minerva Anestesiol 2011; 77: 196-211.
35. Roson B, Carratala J, Verdaguer R, et al. Prospective study of the usefulness of sputum Gram stain in the initial approach to community-Acquired pneumonia requiring hospitalization. Clin Infect Dis 2000; 31: 869-874.
36. Anevlavis S, Petroglou N, Tzavaras A, et al. A prospective study of the diagnostic utility of sputum Gram stain in pneumonia. J Infect 2009; 59: 83-89.
37. Johansson N, Kalin M, Giske CG, et al. Quantitative detection of Streptococcus pneumoniae from sputum samples with real-Time quantitative polymerase chain reaction for etiologic diagnosis of community-Acquired pneumonia. Diagn Microbiol Infect Dis 2008; 60: 255-261.
38. Resti M, Micheli A, Moriondo M, et al. Comparison of the effect of antibiotic treatment on the possibility of diagnosing invasive pneumococcal disease by culture or molecular methods: A prospective, observational study of children and adolescents with proven pneumococcal infection. Clin Ther 2009; 31: 1266-1273.
39. Song JY, Eun BW, Nahm MH. Diagnosis of pneumococcal pneumonia: current pitfalls and the way forward. Infect Chemother 2013; 45: 351-366.
40. Murdoch DR, Anderson TP, Beynon KA, et al. Evaluation of a PCR assay for detection of Streptococcus pneumoniae in respiratory and nonrespiratory samples from adults with community-Acquired pneumonia. J Clin Microbiol 2003; 41: 63-66.
41. Carvalho MG, Tondella ML, McCaustland K, et al. Evaluation and improvement of real-Time PCR assays targeting lytA, ply, and psaA genes for detection of pneumococcal DNA. J Clin Microbiol 2007; 45: 2460-2466.
42. Tuite N, Reddington K, Barry T, et al. Rapid nucleic acid diagnostics for the detection of antimicrobial resistance in Gram-negative bacteria: is it time for a paradigm shift? J Antimicrob Chemother. 2014; 69: 1729-1733.
43. Gadsby NJ, Russell CD, McHugh MP, et al. Comprehensive molecular testing for respiratory pathogens in community-Acquired pneumonia. Clin Infect Dis 2016; 62: 817-823.
44. Wellinghausen N, Siegel D, Gebert S, et al. Rapid detection of Staphylococcus aureus bacteremia and methicillin resistance by real-Time PCR in whole blood samples. Eur J Clin Microbiol Infect Dis 2009; 28: 1001-1005.
45. de Paz HD, Brotons P, Munoz-Almagro C. Molecular isothermal techniques for combating infectious diseases: Towards low-cost point-of-care diagnostics. Expert Rev Mol Diagn 2014; 14: 827-843.
46. Zhang W, Chen C, Cui J, et al. Application of loop-mediated isothermal amplification (LAMP) assay for the rapid diagnosis of pathogenic bacteria in clinical sputum specimens of acute exacerbation of COPD (AECOPD). Int J Clin Exp Med 2015; 8: 7881-7889.
47. Koncan R, Parisato M, Sakarikou C, et al. Direct identification of major Gram-negative pathogens in respiratory specimens by respiFISH® HAP Gram (-) Panel, a beacon-based FISH methodology. Eur J Clin Microbiol Infect Dis 2015; 34: 2097-2102.
48. Mok JH, Eom JS, Jo EJ, et al. Clinical utility of rapid pathogen identification using matrix-Assisted laser desorption/ionization time-of-flight mass spectrometry in ventilated patients with pneumonia: A pilot study. Respirology 2016; 21: 321-328.
49. Zimmerman RK, Rinaldo CR, Nowalk MP, et al. Viral infections in outpatients with medically attended acute respiratory illness during the 2012-2013 influenza season. BMC Infect Dis 2015; 15: 87.
50. Babady NE. The FilmArray® respiratory panel: An automated, broadly multiplexed molecular test for the rapid and accurate detection of respiratory pathogens. Expert Rev Mol Diagn 2013; 13: 779-788.
51. Loeffelholz MJ, Pong DL, Pyles RB, et al. Comparison of the FilmArray Respiratory Panel and Prodesse real-Time PCR assays for detection of respiratory pathogens. J Clin Microbiol 2011; 49: 4083-4088.
52. Cvitkovic SV, Beovic B, Pokorn M, et al. Improvement of pneumococcal pneumonia diagnostics by the use of rt-PCR on plasma and respiratory samples. Scand J Infect Dis 2013; 45: 731-737.
53. Stralin K, Backman A, Holmberg H, et al. Design of a multiplex PCR for Streptococcus pneumoniae, Haemophilus influenzae, Mycoplasma pneumoniae and Chlamydophila pneumoniae to be used on sputum samples. APMIS 2005; 113: 99-111.
54. Stralin K, Herrmann B, Abdeldaim G, et al. Comparison of sputum and nasopharyngeal aspirate samples and of the PCR gene targets lytA and Spn9802 for quantitative PCR for rapid detection of pneumococcal pneumonia. J Clin Microbiol 2014; 52: 83-89.
55. Albrich WC, Madhi SA, Adrian PV, et al. Genomic load from sputum samples and nasopharyngeal swabs for diagnosis of pneumococcal pneumonia in HIV-infected adults. J Clin Microbiol 2014; 52: 4224-4229.
56. Stralin K, Tornqvist E, Kaltoft MS, et al. Etiologic diagnosis of adult bacterial pneumonia by culture and PCR applied to respiratory tract samples. J Clin Microbiol 2006; 44: 643-645.
57. Lorente ML, Falguera M, Nogues A, et al. Diagnosis of pneumococcal pneumonia by polymerase chain reaction (PCR) in whole blood: A prospective clinical study. Thorax 2000; 55: 133-137.
58. Abdeldaim G, Herrmann B, Molling P, et al. Usefulness of real-Time PCR for lytA, ply, and Spn9802 on plasma samples for the diagnosis of pneumococcal pneumonia. Clin Microbiol Infect 2010; 16: 1135-1141.
59. Peters RP, de Boer RF, Schuurman T, et al. Streptococcus pneumoniae DNA load in blood as a marker of infection in patients with community-Acquired pneumonia. J Clin Microbiol 2009; 47: 3308-3312.
60. Avni T, Mansur N, Leibovici L, et al. PCR using blood for diagnosis of invasive pneumococcal disease: systematic review and meta-Analysis. J Clin Microbiol 2010; 48: 489-496.
61. Resti M, Moriondo M, Cortimiglia M, et al. Community-Acquired bacteremic pneumococcal pneumonia in children: diagnosis and serotyping by real-Time polymerase chain reaction using blood samples. Clin Infect Dis 2010; 51: 1042-1049.
62. Albrich WC, Madhi SA, Adrian PV, et al. Use of a rapid test of pneumococcal colonization density to diagnose pneumococcal pneumonia. Clin Infect Dis 2012; 54: 601-609.
63. Abdeldaim GM, Stralin K, Olcen P, et al. Toward a quantitative DNA-based definition of pneumococcal pneumonia: A comparison of Streptococcus pneumoniae target genes, with special reference to the Spn9802 fragment. Diagn Microbiol Infect Dis 2008; 60: 143-150.
64. Rello J, Lisboa T, Lujan M, et al. Severity of pneumococcal pneumonia associated with genomic bacterial load. Chest 2009; 136: 832-840.
65. Cremers AJ, Hagen F, Hermans PW, et al. Diagnostic value of serum pneumococcal DNA load during invasive pneumococcal infections. Eur J Clin Microbiol Infect Dis 2014; 33: 1119-1124.
66. Elberse K, van MS, Cremers AJ, et al. Detection and serotyping of pneumococci in community acquired pneumonia patients without culture using blood and urine samples. BMC Infect Dis 2015; 15: 56.
67. Morozumi M, Chiba N, Okada T, et al. Antibiotic susceptibility in relation to genotype of Streptococcus pneumoniae, Haemophilus influenzae, and Mycoplasma pneumoniae responsible for community-Acquired pneumonia in children. J Infect Chemother 2013; 19: 432-440.
68. Jain S, Self WH, Wunderink RG, et al. Community-Acquired pneumonia requiring hospitalization among US Adults. N Engl J Med 2015; 373: 415-427.
69. Lui G, Ip M, Lee N, et al. Role of 'atypical pathogens' among adult hospitalized patients with communityacquired pneumonia. Respirology 2009; 14: 1098-1105.
70. Arnold FW, Summersgill JT, Lajoie AS, et al. A worldwide perspective of atypical pathogens in communityacquired pneumonia. Am J Respir Crit Care Med 2007; 175: 1086-1093.
71. Cilloniz C, Torres A, Niederman M, et al. Community-Acquired pneumonia related to intracellular pathogens. Intensive Care Med 2016; 42: 1374-1386.
72. Karhu J, la-Kokko TI, Vuorinen T, et al. Lower respiratory tract virus findings in mechanically ventilated patients with severe community-Acquired pneumonia. Clin Infect Dis 2014; 59: 62-70.
73. Lee N, Ison MG. Diagnosis, management and outcomes of adults hospitalized with influenza. Antivir Ther (Lond) 2012; 17: 143-157.
74. Harper SA, Bradley JS, Englund JA, et al. Seasonal influenza in adults and children-diagnosis, treatment, chemoprophylaxis, and institutional outbreak management: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2009; 48: 1003-1032.
75. Chan MC, Lee N, Ngai KL, et al. Clinical and virologic factors associated with reduced sensitivity of rapid influenza diagnostic tests in hospitalized elderly patients and young children. J Clin Microbiol 2014; 52: 497-501.
76. Lee N, Leo YS, Cao B, et al. Neuraminidase inhibitors, superinfection and corticosteroids affect survival of influenza patients. Eur Respir J 2015; 45: 1642-1652.
77. Brendish NJ, Schiff HF, Clark TW. Point-of-care testing for respiratory viruses in adults: The current landscape and future potential. J Infect 2015; 71: 501-510.
78. Bautista E, Chotpitayasunondh T, Gao Z, et al. Clinical aspects of pandemic 2009 influenza A (H1N1) virus infection. N Engl J Med 2010; 362: 1708-1719.
79. Chartrand C, Leeflang MM, Minion J, et al. Accuracy of rapid influenza diagnostic tests: A meta-Analysis. Ann Intern Med 2012; 156: 500-511.
80. Centers for Disease Control and Prevention (CDC). Clinical Description & Lab Diagnosis of Influenza, 2015. http://www.cdc.gov/flu/professionals/diagnosis/. Date last reviewed: 27 October, 2015. Date last updated: 16 December, 2015.
81. Hurt AC, Chotpitayasunondh T, Cox NJ, et al. Antiviral resistance during the 2009 influenza A H1N1 pandemic: public health, laboratory, and clinical perspectives. Lancet Infect Dis 2012; 12: 240-248.
82. Lee N, Chan PK, Hui DS, et al. Viral loads and duration of viral shedding in adult patients hospitalized with influenza. J Infect Dis 2009; 200: 492-500.
83. Li TC, Chan MC, Lee N. Clinical implications of antiviral resistance in influenza. Viruses 2015; 7: 4929-4944.
84. Lee WY, Mokhlesi B. Diagnosis and management of obesity hypoventilation syndrome in the ICU. Crit Care Clin 2008; 24: 533-549.
85. Yeh E, Luo RF, Dyner L, et al. Preferential lower respiratory tract infection in swine-origin 2009 A(H1N1) influenza. Clin Infect Dis 2010; 50: 391-394.
86. Branche AR, Walsh EE, Formica MA, et al. Detection of respiratory viruses in sputum from adults by use of automated multiplex PCR. J Clin Microbiol 2014; 52: 3590-3596.
87. Walsh EE, Peterson DR, Kalkanoglu AE, et al. Viral shedding and immune responses to respiratory syncytial virus infection in older adults. J Infect Dis 2013; 207: 1424-1432.
88. Lee N, Qureshi ST. Other viral pneumonias: coronavirus, respiratory syncytial virus, adenovirus, hantavirus. Crit Care Clin 2013; 29: 1045-1068.
89. Lee N, Lui GC, Wong KT, et al. High morbidity and mortality in adults hospitalized for respiratory syncytial virus infections. Clin Infect Dis 2013; 57: 1069-1077.
90. Zumla A, Al-Tawfiq JA, Enne VI, et al. Rapid point of care diagnostic tests for viral and bacterial respiratory tract infections-needs, advances, and future prospects. Lancet Infect Dis 2014; 14: 1123-1135.
91. Scanvic A, Courdavault L, Sollet JP, et al. Interet de la PCR temps reel Cepheid Xpert SAMR/SA sur GeneXpert® DX System dans la prise en charge de la bacteriemie a staphylocoque [Interest of real-Time PCR Xpert MRSA/SA on GeneXpert® DX System in the investigation of staphylococcal bacteremia]. Pathol Biol (Paris) 2011; 59: 67-72.
92. Prachayangprecha S, Schapendonk CM, Koopmans MP, et al. Exploring the potential of next-generation sequencing in detection of respiratory viruses. J Clin Microbiol 2014; 52: 3722-3730.
93. Phin N, Parry-Ford F, Harrison T, et al. Epidemiology and clinical management of Legionnaires' disease. Lancet Infect Dis 2014; 14: 1011-1021.
94. Lee N, Chan MC, Lui GC, et al. High viral load and respiratory failure in adults hospitalized for respiratory syncytial virus infections. J Infect Dis 2015; 212: 1237-1240.
95. Meyer Sauteur PM, van Rossum AM, Vink C. Mycoplasma pneumoniae in children: carriage, pathogenesis, and antibiotic resistance. Curr Opin Infect Dis 2014; 27: 220-227.
96. Iregui M, Ward S, Sherman G, et al. Clinical importance of delays in the initiation of appropriate antibiotic treatment for ventilator-Associated pneumonia. Chest 2002; 122: 262-268.
97. Kumar A, Ellis P, Arabi Y, et al. Initiation of inappropriate antimicrobial therapy results in a fivefold reduction of survival in human septic shock. Chest 2009; 136: 1237-1248.
98. Thurman KA, Walter ND, Schwartz SB, et al. Comparison of laboratory diagnostic procedures for detection of Mycoplasma pneumoniae in community outbreaks. Clin Infect Dis 2009; 48: 1244-1249.
99. Shimada T, Noguchi Y, Jackson JL, et al. Systematic review and metaanalysis: urinary antigen tests for Legionellosis. Chest 2009; 136: 1576-1585.
100. Murdoch DR, Podmore RG, Anderson TP, et al. Impact of routine systematic polymerase chain reaction testing on case finding for Legionnaires' disease: A pre-post comparison study. Clin Infect Dis 2013; 57: 1275-1281.
101. Martin-Loeches I, Deja M, Koulenti D, et al. Potentially resistant microorganisms in intubated patients with hospital-Acquired pneumonia: The interaction of ecology, shock and risk factors. Intensive Care Med 2013; 39: 672-681.
102. Garnacho-Montero J, Ortiz-Leyba C, Fernandez-Hinojosa E, et al. Acinetobacter baumannii ventilator-Associated pneumonia: Epidemiological and clinical findings. Intensive Care Med 2005; 31: 649-655.
103. Enne VI, Personne Y, Grgic L, et al. Aetiology of hospital-Acquired pneumonia and trends in antimicrobial resistance. Curr Opin Pulm Med 2014; 20: 252-258.
104. Carbonnelle E, Mesquita C, Bille E, et al. MALDI-TOF mass spectrometry tools for bacterial identification in clinical microbiology laboratory. Clin Biochem 2011; 44: 104-109.
105. Sparbier K, Schubert S, Weller U, et al. Matrix-Assisted laser desorption ionization-Time of flight mass spectrometry-based functional assay for rapid detection of resistance against β-lactam antibiotics. J Clin Microbiol 2012; 50: 927-937.
106. Shorr AF, Chan CM, Zilberberg MD. Diagnostics and epidemiology in ventilator-Associated pneumonia. Ther Adv Respir Dis 2011; 5: 121-130.
107. Falcone M, Russo A, Giannella M, et al. Individualizing risk of multidrug-resistant pathogens in communityonset pneumonia. PLoS ONE 2015; 10: E0119528.
108. Jauneikaite E, Tocheva AS, Jefferies JM, et al. Current methods for capsular typing of Streptococcus pneumoniae. J Microbiol Methods 2015; 113: 41-49.
109. Lee B, Boucher HW. Targeting antimicrobial-resistant bacterial respiratory tract pathogens: it is time to 'get smart'. Curr Opin Pulm Med 2015; 21: 293-303.
110. Schulte B, Eickmeyer H, Heininger A, et al. Detection of pneumonia associated pathogens using a prototype multiplexed pneumonia test in hospitalized patients with severe pneumonia. PLoS One 2014; 9: E110566.
111. Charlson ES, Bittinger K, Haas AR, et al. Topographical continuity of bacterial populations in the healthy human respiratory tract. Am J Respir Crit Care Med 2011; 184: 957-963.
112. Vincent JL, Brealey D, Libert N, et al. Rapid diagnosis of infection in the critically ill, a multicenter study of molecular detection in bloodstream infections, pneumonia, and sterile site infections. Crit Care Med 2015; 43: 2283-2291.
113. Dickson RP, Erb-Downward JR, Martinez FJ, et al. The microbiome and the respiratory tract. Annu Rev Physiol 2016; 78: 481-504.
114. Chen C, Shen T, Tian F, et al. New microbiota found in sputum from patients with community-Acquired pneumonia. Acta Biochim Biophys Sin (Shanghai) 2013; 45: 1039-1048.
115. de Steenhuijsen Piters WA, Huijskens EG, Wyllie AL, et al. Dysbiosis of upper respiratory tract microbiota in elderly pneumonia patients. ISME J 2016; 10: 97-108.
116. Abeles SR, Jones MB, Santiago-Rodriguez TM, et al. Microbial diversity in individuals and their household contacts following typical antibiotic courses. Microbiome 2016; 4: 39.